Cargando…

Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis

OBJECTIVE: Mecobalamin is a commonly used drug in the treatment of diabetic peripheral neuropathy (DPN). This study aimed to systematically evaluate the efficacy and safety of acupoint injection of mecobalamin for DPN. METHODS: Relevant clinical trials on acupoint injection of mecobalamin for DPN pu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fei, Yu, Yunfeng, Yin, Shuang, Hu, Gang, Yang, Xinyu, Tong, Keke, Yu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619916/
https://www.ncbi.nlm.nih.gov/pubmed/37920836
http://dx.doi.org/10.3389/fneur.2023.1186420
_version_ 1785130095406481408
author Zhang, Fei
Yu, Yunfeng
Yin, Shuang
Hu, Gang
Yang, Xinyu
Tong, Keke
Yu, Rong
author_facet Zhang, Fei
Yu, Yunfeng
Yin, Shuang
Hu, Gang
Yang, Xinyu
Tong, Keke
Yu, Rong
author_sort Zhang, Fei
collection PubMed
description OBJECTIVE: Mecobalamin is a commonly used drug in the treatment of diabetic peripheral neuropathy (DPN). This study aimed to systematically evaluate the efficacy and safety of acupoint injection of mecobalamin for DPN. METHODS: Relevant clinical trials on acupoint injection of mecobalamin for DPN published before 31 January 2023 were searched in eight commonly used databases. After screening and confirming the included studies, meta-analysis and trial sequential analysis were performed. RESULTS: A total of 10 relevant studies were confirmed, and the total sample size was 927 cases. On the efficacy endpoints, meta-analysis showed that compared with other administration methods, acupoint injection of mecobalamin significantly increased the clinical effective rate by 27% [RR = 1.27, 95% CI = (1.19, 1.36), P < 0.00001], motor nerve conduction velocity (median nerve) by 5.93 m/s [MD = 5.93, 95% CI = (4.79, 7.07), P < 0.00001], motor nerve conduction velocity (common peroneal nerve) by 5.66 m/s [MD = 5.66, 95% CI = (2.89, 8.43), P < 0.0001], sensory nerve conduction velocity (median nerve) by 4.83 m/s [MD = 4.83, 95% CI = (3.75, 5.90), P < 0.00001], and sensory nerve conduction velocity (common peroneal nerve) by 3.60 m/s [MD = 3.60, 95% CI = (2.49, 4.71), P < 0.00001], and trial sequential analysis showed these benefits were conclusive. In terms of safety endpoints, meta-analysis indicated that the total adverse events for acupoint injection were comparable to other methods of administration, and trial sequential analysis suggested that the results needed to be validated by more studies. Subgroup analysis demonstrated that the benefits of acupoint injections of mecobalamin were not limited by the dose, duration of treatment, or number of acupoints reported in the included studies. Harbord's test showed no significant publication bias (P = 0.106). CONCLUSION: The efficacy of acupoint injection of mecobalamin for DPN was significantly better than other administrations, and its safety was comparable to other administrations. Therefore, acupoint injection may be the optimal method of mecobalamin for DPN. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=454120, identifier: CRD42023454120.
format Online
Article
Text
id pubmed-10619916
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106199162023-11-02 Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis Zhang, Fei Yu, Yunfeng Yin, Shuang Hu, Gang Yang, Xinyu Tong, Keke Yu, Rong Front Neurol Neurology OBJECTIVE: Mecobalamin is a commonly used drug in the treatment of diabetic peripheral neuropathy (DPN). This study aimed to systematically evaluate the efficacy and safety of acupoint injection of mecobalamin for DPN. METHODS: Relevant clinical trials on acupoint injection of mecobalamin for DPN published before 31 January 2023 were searched in eight commonly used databases. After screening and confirming the included studies, meta-analysis and trial sequential analysis were performed. RESULTS: A total of 10 relevant studies were confirmed, and the total sample size was 927 cases. On the efficacy endpoints, meta-analysis showed that compared with other administration methods, acupoint injection of mecobalamin significantly increased the clinical effective rate by 27% [RR = 1.27, 95% CI = (1.19, 1.36), P < 0.00001], motor nerve conduction velocity (median nerve) by 5.93 m/s [MD = 5.93, 95% CI = (4.79, 7.07), P < 0.00001], motor nerve conduction velocity (common peroneal nerve) by 5.66 m/s [MD = 5.66, 95% CI = (2.89, 8.43), P < 0.0001], sensory nerve conduction velocity (median nerve) by 4.83 m/s [MD = 4.83, 95% CI = (3.75, 5.90), P < 0.00001], and sensory nerve conduction velocity (common peroneal nerve) by 3.60 m/s [MD = 3.60, 95% CI = (2.49, 4.71), P < 0.00001], and trial sequential analysis showed these benefits were conclusive. In terms of safety endpoints, meta-analysis indicated that the total adverse events for acupoint injection were comparable to other methods of administration, and trial sequential analysis suggested that the results needed to be validated by more studies. Subgroup analysis demonstrated that the benefits of acupoint injections of mecobalamin were not limited by the dose, duration of treatment, or number of acupoints reported in the included studies. Harbord's test showed no significant publication bias (P = 0.106). CONCLUSION: The efficacy of acupoint injection of mecobalamin for DPN was significantly better than other administrations, and its safety was comparable to other administrations. Therefore, acupoint injection may be the optimal method of mecobalamin for DPN. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=454120, identifier: CRD42023454120. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10619916/ /pubmed/37920836 http://dx.doi.org/10.3389/fneur.2023.1186420 Text en Copyright © 2023 Zhang, Yu, Yin, Hu, Yang, Tong and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Zhang, Fei
Yu, Yunfeng
Yin, Shuang
Hu, Gang
Yang, Xinyu
Tong, Keke
Yu, Rong
Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis
title Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis
title_full Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis
title_fullStr Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis
title_full_unstemmed Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis
title_short Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis
title_sort is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? a meta-analysis and trial sequential analysis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619916/
https://www.ncbi.nlm.nih.gov/pubmed/37920836
http://dx.doi.org/10.3389/fneur.2023.1186420
work_keys_str_mv AT zhangfei isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis
AT yuyunfeng isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis
AT yinshuang isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis
AT hugang isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis
AT yangxinyu isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis
AT tongkeke isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis
AT yurong isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis